{
    "symbol": "AXSM",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-09 14:58:16",
    "content": " We believe that our current cash balance, along with the remaining committed capital from the $300 million term loan facility with Hercules Capital, is sufficient to fund anticipated operations into 2024 based on our current operating plan which includes the commercialization of Sunosi and the potential launch of AXS-05 in MDD, if approved, along with continued development of our pipeline. So we want to make sure that -- so while this new study technically would not be required for an NDA filing in Alzheimer's disease agitation, assuming that the randomized withdrawal study, let's say, is positive, we think that it's prudent to have more than one shot on goal and to have two studies, both of which are parallel group that would replicate each other."
}